Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug stops Post-Birth bleeding best? new trial has answers

NCT ID NCT03584854

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two medications, methylergonovine and carboprost, to treat heavy bleeding after a C-section when the first drug (oxytocin) doesn't work. 100 women with postpartum hemorrhage due to a relaxed uterus were randomly assigned to one drug. Doctors measured how well the uterus tightened up. The goal is to find which drug works better to stop dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylergonovine and carboprost
What this could lead to
If one drug works better, it could become the preferred second-line treatment for severe bleeding after childbirth, improving outcomes for mothers.
What could go wrong
This is a small, completed trial with only 100 participants, so results may not apply to all women. The drugs also have side effects like high blood pressure or breathing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Mar 2019

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * non-emergent cesarean delivery * ASA I-III * postpartum hemorrhage deemed the result of uterine atony (uterine atony at the time of delivery, despite the administration of oxytocin) Exclusion Criteria: * non-English speaking patients requiring an interpreter for urgent, unscheduled delivery * any hypertensive disorder * cardiovascular disease * asthma * refusal of transfused blood products * coagulopathy or abnormal coagulation lab values * hypersensitivity to methylergonovine maleate or 15-methyl prostaglandin * known or suspected delayed postpartum hemorrhage after leaving the operating room

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage Uterine Inertia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum hemorrhage Uterine atony

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.